Previous breast cancer studies analyzed tumor tissues utilizing cDNA microarray and sequencing and identified markers of drug resistance such as CSNK2B, DDB1, ABL, PRKDC, and DUSP4 that were differentially expressed between responders and non‐responders to NAT (Chang et al, 2003; Balko et al, 2012). This evidence concerns the gene BRD2 and breast carcinoma.